Coldstream Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Coldstream Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$166K	Sell	10,332 -5,115	-33%	-$84.6K	﹤0.01%	1184
2026 Q1	$286K	Buy	+15,447	New	+$271K	﹤0.01%	960
2025 Q4	–	Sell	-23,828	Closed	-$349K	–	1257
2025 Q3	$349K	Buy	23,828 +13,765	+137%	+$204K	﹤0.01%	874
2025 Q2	$156K	Buy	10,063 +1,577	+19%	+$23.3K	﹤0.01%	1081
2025 Q1	$126K	Buy	+8,486	New	+$119K	﹤0.01%	1227

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Coldstream Capital Management's TAK Position: Q2 2026 in Review

Coldstream Capital Management reduced its Takeda Pharmaceutical (TAK) stake by 33% in Q2 2026, selling an estimated $84.6K and leaving 10,332 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #1184.

Coldstream Capital Management first reported a position in TAK in Q1 2025 and has held it in 5 quarters since. The position peaked at $349K in Q3 2025. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Coldstream Capital Management held 10,332 shares of Takeda Pharmaceutical worth $166K as of Q2 2026.
Coldstream Capital Management sold 5,115 Takeda Pharmaceutical shares in Q2 2026, an estimated $84.6K.
Takeda Pharmaceutical made up ﹤0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #1184 holding.
Coldstream Capital Management first reported a position in Takeda Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
Coldstream Capital Management's Takeda Pharmaceutical position peaked at $349K in Q3 2025.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.